von Biberstein S E, Spiro J D, Lindquist R, Kreutzer D L
Department of Surgery, University of Connecticut Health Center, Farmington, USA.
Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):751-9. doi: 10.1001/archotol.1996.01890190047012.
We hypothesized that in head and neck squamous cell carcinoma, the overexpression of protumorigenic interleukin-1 (IL-1) activity within the tumor tissue is a result of decreased expression of the specific antagonist or inhibitor (ie, IL-1 receptor antagonist) by the tumor cells. Ultimately, this local overexpression of IL-1 activity increases tumor growth and metastasis.
To test our hypotheses, immunologic analysis for IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist was performed on histologic sections and tumor homogenates of human head and neck squamous cell carcinomas.
University teaching hospital.
Normal and tumor specimens were obtained from patients undergoing surgical resections of the head and neck for benign and malignant disease.
Immunohistochemical analysis demonstrated the presence of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist within tumor cells and inflammatory cells in the tumor stroma in 19 of 19 tumor specimens. Quantitatively, IL-1 alpha was present in 19 of 19 tumor specimens (1.97 +/- 0.46 ng/mg of total protein [mean +/- SD]) and 5 of 9 normal specimens (0.23 +/- 0.12 ng/mg of total protein). All specimens contained IL-1 beta in detectable quantities (1.60 +/- 0.29 ng/mg of total protein in tumor specimens and 0.189 +/- 0.04 ng/mg of total protein in normal specimens). All specimens contained IL-1 receptor antagonist (368.87 +/- 57.63 ng/mg of total protein in tumor specimens and 585.10 +/- 166.03 ng/mg of total protein in normal specimens). The mean total IL-1/IL-1 receptor antagonist ratio was 13.26 +/- 2.31 in patients with cancer compared with 0.997 +/- 0.26 in normal patients.
The increased IL-1 index in the cancer state compared with the normal state reflects an imbalance of IL-1 and IL-1 receptor antagonist, which may contribute to unrestricted growth and metastasis of head and neck squamous cell carcinoma.
我们推测，在头颈部鳞状细胞癌中，肿瘤组织内促肿瘤的白细胞介素-1（IL-1）活性的过表达是肿瘤细胞中特异性拮抗剂或抑制剂（即IL-1受体拮抗剂）表达降低的结果。最终，这种IL-1活性的局部过表达会促进肿瘤生长和转移。
为验证我们的假设，对人头颈部鳞状细胞癌的组织学切片和肿瘤匀浆进行了IL-1α、IL-1β和IL-1受体拮抗剂的免疫分析。
大学教学医院。
正常和肿瘤标本取自因良性和恶性疾病接受头颈部手术切除的患者。
免疫组织化学分析显示，在19份肿瘤标本中的肿瘤细胞和肿瘤基质中的炎性细胞内均存在IL-1α、IL-1β和IL-1受体拮抗剂。定量分析表明，19份肿瘤标本中有19份存在IL-1α（总蛋白含量为1.97±0.46 ng/mg[平均值±标准差]），9份正常标本中有5份存在IL-1α（总蛋白含量为0.23±0.12 ng/mg）。所有标本中均含有可检测量的IL-1β（肿瘤标本中总蛋白含量为1.60±0.29 ng/mg，正常标本中总蛋白含量为0.189±0.04 ng/mg）。所有标本中均含有IL-1受体拮抗剂（肿瘤标本中总蛋白含量为368.87±57.63 ng/mg，正常标本中总蛋白含量为585.10±166.03 ng/mg）。癌症患者的总IL-1/IL-1受体拮抗剂平均比值为13.26±2.31，而正常患者为0.997±0.26。
与正常状态相比，癌症状态下IL-1指数升高反映了IL-1与IL-1受体拮抗剂之间的失衡，这可能有助于头颈部鳞状细胞癌的无限制生长和转移。
